Eslicarbazepine Acetate (BIA 2-093)

Neurotherapeutics

Volumn 4, Issue 1, 2007, Pages 88-96

  Almeida, Luis ^a   Soares da Silva, Patrício ^a  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

Author keywords

antiepileptic drugs; BIA 2 093; drug therapy; epilepsy; Eslicarbazepine acetate

Indexed keywords

10 ACETOXY 10,11 DIHYDRO 5H DIBENZ[B,F]AZEPINE 5 CARBOXAMIDE; 4 AMINOPYRIDINE; ANTICONVULSIVE AGENT; BIA 2 005; BICUCULLINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CREATINE KINASE; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIAZEPAM; DIGOXIN; DRUG METABOLITE; ESLICARBAZEPINE ACETATE; GLUTAMATE RECEPTOR; LICARBAZEPINE; OXCARBAZEPINE; PENTETRAZOLE; PHENYTOIN; PICROTOXIN; PLACEBO; PLASMA PROTEIN; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VOLTAGE GATED SODIUM CHANNEL; WARFARIN;

ANIMAL BEHAVIOR; ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR DISORDER; BINDING AFFINITY; BIPOLAR DISORDER; CIRCUMORAL PARESTHESIA; CLINICAL TRIAL; DIZZINESS; DROWSINESS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTRIC SHOCK; ELECTROENCEPHALOGRAM; EPILEPSY; FOCAL EPILEPSY; HAIR LOSS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; INSOMNIA; KINDLING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MENTAL CONCENTRATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP WAKING CYCLE; SOLID PHASE EXTRACTION; STEADY STATE; VOMITING; XEROSTOMIA;

ANIMALS; ANTICONVULSANTS; BRAIN; CLINICAL TRIALS; DIBENZAZEPINES; EPILEPSY; HUMANS;

EID: 33846184701     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2006.10.005     Document Type: Article

References (25)

1. Benes J., Parada A., Figueiredo A.A., et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem 42 (1999) 2582-2587
2. Parada A., and Soares-da-Silva P. The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. Neurochem Int 40 (2002) 435-440
3. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 15 (2006) 637-647
4. Almeida L., and Soares-da-Silva P. Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs R D 4 (2003) 269-284
5. Almeida L., and Soares-da-Silva P. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol 44 (2004) 906-918
6. Fontes-Ribeiro C., Nunes T., Falcão A., et al. Eslicarbazepine acetate (BIA 2-093): relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulations. Drugs R D 6 (2005) 253-260
7. Bonifacio M.J., Sheridan R.D., Parada A., Cunha R.A., Patmore L., and Soares-da-Silva P. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 42 (2001) 600-608
8. Ambrosio A.F., Silva A.P., Araujo I., et al. Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. Eur J Pharmacol 406 (2000) 191-201
9. Ambrosio A.F., Silva A.P., Malva J.O., Soares-da-Silva P., Carvalho A.P., and Carvalho C.M. Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem Pharmacol 61 (2001) 1271-1275
10. Cunha R.A., Coelho J.E., Costenla A.R., et al. Effects of carbamazepine and novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives on synaptic transmission in rat hippocampal slices. Pharmacol Toxicol 90 (2002) 208-213
11. Araujo I.M., Ambrosio A.F., Leal E.C., et al. Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093. Epilepsia 45 (2004) 1498-1505
12. Bialer M., Johannessen S., Kupferberg H.J., Levy R.H., Perucca E., and Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh EILAT Conference (EILAT VII). Epilepsy Res 61 (2004) 1-48
13. Sierra-Paredes G., Oreiro-Garcia M.T., Nuñez-Rodriguez A., Vazquez-Lopez A., and Sierra-Marcuño G. Effect of novel anticonvulsant BIA 2-093 on seizures induced by picrotoxin microperfusion in the rat hippocampus. Epilepsia 45 Suppl 3 (2004) 116
14. Sierra-Marcuño G., Oreiro-García M.T., Vázquez-Illanes M.D., and Sierra-Paredes G. Effect of novel anticonvulsant BIA 2-093 on latrunculin A-induced seizures and extracellular glutamate concentrations in the rat hippocampus. Epilepsia 46 Suppl 8 (2005) 302 Abstract
15. Almeida L., Falcão A., Maia J., Mazur D., Gellert M., and Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 45 (2005) 1062-1066
16. Silveira P., Falcão A., Almeida L., Maia J., and Soares-da-Silva P. BIA 2-093 pharmacokinetics in healthy elderly subjects. Epilepsia 45 Suppl 3 (2004) 157 Abstract
17. Soares-da-Silva P., Almeida L., Falcão A., and Maia J. Effect of age and gender on the pharmacokinetics of eslicarbazepine acetate. Epilepsia 46 Suppl 8 (2005) 216-217 Abstract
18. Vaz-da-Silva M., Nunes T., Soares E., et al. Eslicarbazepine acetate pharmacokinetics after single and repeated doses in healthy subjects. Epilepsia 46 Suppl 8 (2005) 191 Abstract
19. Maia J., Vaz-da-Silva M., Almeida L., et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R D 6 (2005) 201-206
20. EMEA-CPMP. Note for guidance on the investigation of bioavailability and bioequivalence (2001). http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf Presented at the European Agency for the Evaluation of Medicinal Products-Committee for Proprietary Medicinal Products, CPMP/EWP/QWP/1401/9; Jul 26. Available at: http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf.
21. Maia J., Almeida L., Vaz-da-Silva M., et al. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics of digoxin in healthy subjects. Epilepsia 46 Suppl 8 (2005) 178-179 Abstract
22. Fattore C., Cipolla G., Gatti G., et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 40 (1999) 783-787
23. Back D.J., and Orme M.L.E. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 18 (1990) 472-484
24. Fotherby K. Levonorgestrel: clinical pharmacokinetics. Clin Pharmacokinet 28 (1995) 203-215
25. Almeida L., Maia J., and Soares-da-Silva P. A double-blind, add-on, placebo-controlled, exploratory trial of eslicarbazepine acetate in patients with partial-onset seizures. Epilepsia 46 Suppl 8 (2005) 167-168